New #Stocks in Biotech (Nasdaq: $TELA) Cannabis (CSE: $HFH.C), Crypto (CSE: $LNK.C) and eSports (CSE: $NWES.C) at Investor Ideas
Point Roberts WA, Delta BC, November 22, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in biotech, cannabis, China-Asia, crypto and eSports.
Read this in full at https://www.investorideas.com/news/2019/main/11221Stocks.asp
This week’s new biotech companies include multiple Nasdaq IPO’s which are involved in biopharmaceuticals, medical technology and biotechnologies.
The newest cannabis companies are both listed on Canadian Exchanges (TSXV & CSE) and are involved in CBD products, including pharmaceutical cannabidiol.
The latest China-Asia companies are also Nasdaq IPO’s and cross over into the tech, cloud, Health and Wellness and real estate sectors.
The newest crypto company is the Canadian Stock Exchange listed Link Global Technologies Inc. (CSE: LNK) which provides infrastructure and operating expertise for cryptocurrency mining and blockchain technologies, while the latest eSports company is also CSE listed and provides capital and support services to esports organizations, teams, leagues, events, platforms, tools, and technology innovators.
New Biotech Companies
TELA Bio, Inc. (NasdaqGM:TELA) is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA’s products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.
Centogene N.V. (NasdaqGM:CNTG) is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. Centogene has developed a global proprietary rare disease platform based on our real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing 115 different countries as of August 31, 2019, or an average of over 500 data points per patient. The Company’s platform includes epidemiologic, phenotypic and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. Centogene believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2019, the Company collaborated with over 35 pharmaceutical partners for over 30 different rare diseases
Galera Therapeutics, Inc. (NasdaqGM:GRTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is GC4419 (avasopasem manganese), a highly selective and potent small molecule dismutase mimetic that is designed to rapidly convert superoxide to hydrogen peroxide. GC4419 is being studied in the Phase 3 ROMAN trial for its ability to reduce the duration, incidence and severity of radiation-induced severe oral mucositis in patients with locally advanced head and neck cancer, its lead indication. The FDA granted Fast Track and Breakthrough Therapy designations to GC4419 for the reduction of the duration, incidence and severity of severe oral mucositis induced by radiotherapy. Galera is headquartered in Malvern, PA.
CNS Pharmaceuticals, Inc. (NasdaqCM:CNSP) is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphonas. The Company entered into an IP agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata Pharmaceuticals Inc.
Iovance Biotherapeutics, Inc.(NasdaqGS: IOVA) intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company is currently conducting pivotal studies in patients with metastatic melanoma and advanced cervical cancer. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. Clinical studies of T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy are being planned.
New Cannabis Companies:
Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx™, is designed to be one of the safest and most consistent CBD formulations on the market. CardiolRx is pharmaceutically produced, cGMP certified, and is THC free. The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is also pursuing distribution opportunities in Europe and Latin America. In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion
Hemp for Health Inc. (CSE:HFH) is a cultivator and distributor of premium CBD products. The company has an exclusive, long-term contract for land with farmers in the Tuscan region of Italy to achieve their purpose of yielding high quality CBD extracts. The company’s goal is to offer superior natural and organic CBD products, starting with pristine soil, seeds and sun.
New China-Asia Companies
ECMOHO Limited (NasdaqGM:MOHO) operates as an integrated solution provider in the non-medical health and wellness market. The company acts as a bridge between brand owners and consumers by marketing and distributing health supplements and food, mother and child care products, personal care products, household healthcare equipment, and other health and wellness products.
Fangdd Network Group Ltd. (NasdaqGM:DUO) is a leading property technology company in China. Through innovative use of mobile internet, cloud and big data, FangDD has fundamentally revolutionized the way real estate agents conduct business through a suite of modular products and services powered by technology. FangDD operates China’s largest online real estate marketplace as measured by the number of registered agents on its marketplace as of December 31, 2018. Of the approximately 2.0 million real estate agents in China, more than 911,000 were on its platform as of December 31, 2018, representing a penetration rate of over 45%.
Q&K International Group Limited (NasdaqGM:QK) is a leading technology-driven long-term apartment rental platform in China. The Company offers young, emerging urban residents conveniently-located, ready-to-move-in, and affordable branded apartments as well as facilitates a variety of value-added services. Qingke signs long-term leases with individual landlords in different locations in relatively inexpensive yet convenient locations and manages them centrally, leveraging its advanced IT and mobile technologies. Technology is at the core of Qingke’s business and is applied to every step of its operational process from apartment sourcing, renovation, and tenant acquisition, to property management. The focus on technology enables Qingke to operate a large, dispersed, and fast-growing portfolio of apartments with high operational efficiency and deliver a superior user experience.
36Kr Holdings Inc. (NasdaqGM:KRKR) is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China’s New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services and subscription services to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by comprehensive database and strong data analytics capabilities. Through diverse service offerings and the significant brand influence, the Company is well-positioned to continuously capture the high growth potentials of China’s New Economy.
New Crypto Companies
Link Global Technologies Inc. (CSE: LNK) is engaged in the business of providing infrastructure and operating expertise for cryptocurrency mining and blockchain technology, and of locating and securing, for lease and option to purchase, properties with access to low-cost reliable power and deploying the low-cost power to conduct digital mining and to supply energy for other data hosting services. Link is headquartered in Vancouver, British Columbia and carries out cryptocurrency mining activities in Boardman, Oregon, USA and Beaver Falls, British Columbia. It mines cryptocurrency coins with its own computing power.
New Esports Companies
NEW WAVE ESPORTS CORP. (CSE:NWES) is an esports and competitive gaming company that provides capital and support services to esports organizations, teams, leagues, events, platforms, tools, and technology innovators. New Wave Esports has leadership teams located in Toronto, Ontario and Los Angeles, California.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining, the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Learn more about our news, PR and social media services at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
To sponsor a daily podcast for the month or to be an expert guest please contact us!